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http://dx.doi.org/10.1016/j.jfma.201Persistent pulmonary hypertension of the newborn (PPHN) is a severe pulmonary disorder
which occurs at a rate of one in every 500 live births. About 10e50% of the victims will die
of the problem and 7e20% of the survivors develop long-term impairments such as hearing
deficit, chronic lung disease, and intracranial bleed. Most adult survivors show evidence of
augmented pulmonary vasoreactivity, suggesting a phenotypical change. Several animal
models have been used to study the pathophysiology and help to develop new therapeutic
modality for PPHN. The etiology of PPHN can be classified into three groups: (1) abnormally
constricted pulmonary vasculature as a result of parenchymal diseases; (2) hypoplastic pulmo-
nary vasculature; and (3) normal parenchyma with remodeled pulmonary vasculature.
Impaired vasorelaxation of pulmonary artery and reduced blood vessel density in lungs are
two characteristic findings in PPHN. Medical treatment includes sedation, oxygen, mechanical
ventilation, vasorelaxants (inhaled nitric oxide, inhaled or intravenous prostacyclin, intrave-
nous prostaglandin E1, magnesium sulfate), and inotropic agents. Phosphodiesterase inhibitors
have recently been studied as another therapeutic agent for PPHN. Endothelin-1 (ET-1) inhib-
itors have been studied in animals and a case of premature infant with PPHN successfully
treated with an ET-I inhibitor has been reported in the literature. Surfactants have been re-
ported as an adjunct treatment for PPHN as a complication of meconium aspiration syndrome.
Even with the introduction of several new therapeutic modalities there has been no significant
change in survival rate. Extracorporeal membrane oxygenator is used when medical treatment
fails and the patient is considered to have a recoverable cause of PPHN.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Neonatology, Department of
nsin, C410, 999 North 92nd
.-J. Teng).
ight ª 2012, Elsevier Taiwan LLC
2.11.007Introduction
Persistent pulmonary hypertension of the newborn (PPHN)
is a frequent cause of hypoxemic respiratory failure in term
and late preterm infants affecting 0.43e6.8 per 1000 live& Formosan Medical Association. All rights reserved.
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birth, but occasionally can be a consequence of other
diseases, such as severe respiratory distress syndrome, or
secondary to the management of other perinatal disorders,
such as body cooling for hypoxiceischemic encephalopathy
and slowly develops several hours or even days of birth.
With the introduction of inhaled nitric oxide (INO) the
management of PPHN is easier than it was a decade ago,
but the mortality rate remains unchanged and a high
percentage of PPHN survivors carry long-term sequelae
including chronic oxygen dependence, stroke or impaired
hearing. In this review we describe the physiology of the
perinatal transition, some commonly used animal models
that help us to understand the pathophysiology of PPHN,
etiology and risk factors for PPHN, and recent strategies in
PPHN management.
Animal models of PPHN
Several animal models have been used to elucidate the
pathophysiology of PPHN including intra-uterine ductus
arteriosus ligation of fetal lamb or piglet, acute or
chronic hypoxic pulmonary hypertension of newborn
animals,2,3 intratracheal meconium instillation,4 creation
of aortopulmonary shunt,5 and intra-uterine nonsteroidal
anti-inflammatory drug (NSAID) or selective serotonin re-
uptake inhibitor (SSRI) exposure.6 Each model has its pros
and cons and readers should refer to each published model
for details. Most animal models show smooth muscle layer
thickening of the pulmonary arteries and thickened right
ventricular wall. Other described findings include
decreased blood vessel density of the lungs, impaired
endothelial nitric oxide synthase (eNOS) activity, increased
endothelin-1 (ET-1) formation, increased reactive oxygen
species (ROS) formation,7 and impaired alveolar formation.
The increased ROS formation can stimulate the prolifera-
tion of smooth muscle cells8 and increases activity of
phosphodiesterases (PDE) that enhance the hydrolysis of
cyclic guanosine monophosphate (cGMP).
Physiology of perinatal transition
Many structural and functional changes occur during fetal
lung development to prepare the lung for the transition to
air breathing. The development of pulmonary vasculature is
genetically controlled and pulmonary vessels acquire
increased vasoreactivity with advancing gestation. An
extensive review was recently published and readers who
are interested in this topic are encouraged to read this
article.9 Before birth, the lungs are filled with fluid and the
pulmonary artery resistance is very high, because of low
oxygen tension in the alveoli, and most of the blood
returning to the right atrium goes through the foramen
ovale into the left atrium. Blood entering the right ventricle
also shunts through the ductus arteriosus into the aorta
leaving only a small amount of blood flowing into the lungs.
The first breath after birth allows air to enter into the
alveoli with a dramatic reduction in pulmonary artery
resistance secondary to increased oxygen tension. The
sudden increase of oxygen tension from 20 torr to 150 torr
(0.15 to 1.125 Pascal) increases mitochondrial oxidativephosphorylation and adenosine triphosphate (ATP) produc-
tion. The surge in blood ATP levels during the postnatal
transition can stimulate eNOS function with production of
NO and pulmonary vasorelaxation.10
Several vasoactive substances are known to modulate
the vasomotor tone of the pulmonary artery. Endothelin-1
(ET-1), nitric oxide (NO) and prostacyclin (PGI2) are the
most extensively studied in PPHN. Thromboxane A2 is
another product of the cyclo-oxygenase and thromboxane
synthase system that plays some role mainly during infec-
tions associated with PPHN. Voltage-gated potassium (Kv)
channels which modulate vascular smooth muscle
contraction also play an important role in PPHN.11 ET-1 is
a vasoconstrictor to the pulmonary arteries and enhances
O2
 formation that depletes NO bioavailability and promotes
the growth of the pulmonary artery muscular layer. When
pulmonary artery resistance fails to decrease during the
perinatal transition the deoxygenated blood shunts from
right to left through either the foramen ovale (no differ-
ential cyanosis) or ductus arteriosus (with differential
cyanosis) with PPHN. Most venous return from the inferior
vena cava goes through the foramen ovale whereas most
blood returning from the superior vena cava tends to go
into the main pulmonary trunk (Fig. 1).
Endothelial NOS, or nitric oxide synthase type 3 (NOS3) is
the most extensively studied enzyme in PPHN. Unstimu-
lated eNOS is believed to bind to caveolin-1.12 When acti-
vated by shear stress or ATP, eNOS departs caveolin and
become phosphorylated to form a dimer. The eNOS dimer
then associates with heat shock protein 90 (hsp90) in the
presence of tetrahydrobiopterin (BH4), calcium, flavin
adenine dinucleotide (FAD), flavin mononucleotide (FMN),
iron and L-arginine to be “coupled” to convert L-arginine
into NO and L-citrullin (Fig. 2). BH4 depletion and hypo-
calcemia can both uncouple eNOS and lead to O2
 forma-
tion. Hypoglycemia leads to low FAD or FMN levels in
endothelial cells which may also uncouple eNOS. L-Arginine
is not only the substrate for eNOS: its presence can also
help eNOS coupling. If arginase-II activity is increased,
L-arginine is converted into asymmetric dimethylarginine
(ADMA) which inhibits eNOS function.Etiology of PPHN
The etiology of PPHN can be classified into three main
categories (Table 1). The most common is PPHN secondary
to parenchymal diseases, including meconium aspiration
syndrome (MAS), severe respiratory distress syndrome, RDS
and pneumonia. This is mainly caused by poor oxygen entry
into the alveolar space, especially in MAS with obstruction in
the airways. Inadequate blood vessel density with decreased
total cross-section of pulmonary vasculature and increased
pulmonary vascular resistance is the cause of PPHN in
congenital diaphragmatic hernia. The least common etiology
is normal parenchyma with remodeled pulmonary vascula-
ture, such as idiopathic PPHN, congenital heart disease, and
chronic intrauterine hypoxia. Some congenital heart
diseases are associated with obstructed pulmonary venous
return which can lead to secondary increased pulmonary
artery resistance. Hypoxiceischemic encephalopathy
caused by chronic intra-uterine hypoxia may remodel the
Figure 1 Blood flow pattern of persistent pulmonary hyper-
tension of the newborn (PPHN). Two potential right-to-left
shunts, either through the foramen ovale or ductus arterio-
sus, can be observed in PPHN. There is a differential cyanosis if
the right-to-left shunt is through the ductus. Venous blood
from the superior vena cava preferentially flows through the
right ventricle into the main pulmonary artery so an intrave-
nous vasorelaxant should be given via an intravenous catheter
placed in the upper part of the body. Most venous blood from
the inferior vena cava flows directly through the foramen ovale
when PPHN is present so inotropic agents should be given
through a catheter placed in the lower part of the body.
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increased ET-1 production that increases pulmonary vascular
resistance. Idiopathic PPHN is the rarest cause of PPHN,
usually with normal chest X-ray findings. There are some
metabolic, or genetic, disorders that can present with PPHN.
Pearson et al reported heterozygote T1405N genotype for
carbamoyl-phosphate synthetase, an enzyme that deter-
mines the blood levels of arginine and citrulline, and is
associated with PPHN possible because of a lack of substrate
for eNOS.13 Epidemiologic study demonstrated that Black
and Asian maternal race is associated with a significant
higher risk for PPHN. Male gender also leads to higher inci-
dence of PPHN.14 Although it is hard to decipher the obser-
vations, the evidence suggests some genetic predisposition
to PPHN and deserves further exploration.
Pathology of PPHN
Decreased vascular density and a thickened smooth muscle
layer of the pulmonary artery are the two most commonpathological findings in PPHN. Morphometric analysis of
PPHN lungs reveals extension of muscle into small pulmo-
nary arteries: all alveolar duct and wall arteries (<30 mm
external diameter), normally nonmuscular, are fully
musularized. The medial wall thickness of the normally
muscular intra-acinar arteries is doubled; arterial size and
number, however, are normal in all.15 A decreased number
of alveoli is seen in lung hypoplasia and congenital dia-
phragmatic hernia.
Symptoms and signs
In developing countries post-term infants and intra-
uterine growth restriction (IUGR) are the major groups
to have PPHN, so dry and peeled skin is commonly seen.
Meconium passage or lack of subcutaneous fat tissue is
commonly observed in IUGR and post-term neonates.
General cyanosis is the typical presentation of PPHN, but
sometimes we can observe so-called differential cyanosis
with preductal skin less cyanotic than the postductal skin
unless transposition of the great arteries (TGA) is also
present. When PPHN is associated with TGA then reversed
differential cyanosis can be seen. The routine hyperoxia
challenge usually cannot help the diagnosis, because
severe PPHN can behave like typical cyanotic congenital
heart disease and does not respond to high oxygen
challenge.
Diagnosis and evaluation
Echocardiography is the most convenient and reliable
method for establishing the diagnosis. Poor myocardial
contractility, poor movement of the interventricular
septum, deviation of the interatrial septum to the left,
turbulent flow for tricuspid regurgitation, or shunt through
the ductus arteriosus can be used to evaluate the cause and
severity of the PPHN. Pulmonary arterial accelerating time,
and maximal velocity of the tricuspid regurgitation can be
used to estimate the pulmonary artery pressure. Major
complex congenital heat disease has to be ruled out by
echocardiography prior to extracorporeal membrane
oxygenator (ECMO) treatment. Infusion of normal saline
through a venous line placed below the diaphragm which
creates a microbubble picture can be used to demonstrate
the interatrial right-to-left shunt, either through a patent
foramen of ovales or a patent ductus arteriosus, as
supportive evidence for PPHN. Very rarely PPHN can be the
consequence of obstructive type total anomalous pulmo-
nary venous return, which does not respond to usual PPHN
treatment, and this can only be ruled out with echocardi-
ography. Echocardiography is also a mandatory study
before initiation of ECMO because it is necessary to rule out
possible lethal cyanotic congenital heart disease that
cannot be corrected by heart surgery.
Risk factors
Some risk factors for PPHN have been reported in the
literature. However, the true mechanism remains obscure
for most of them.
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Figure 2 Controls of the endothelial nitric oxide synthase (eNOS) function. Shear stress in a blood vessel activates eNOS
expression and activity. When activated, eNOS is free from the association with caveolin-1 and forms a dimer and becomes
phosphorylated. eNOS then binds to heat shock protein 90 (hsp90), calmodulin, and in the presence of tetrahydrobiopterin (BH4),
calcium, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) is activated. Once activated, eNOS converts L-arginine
into citrullin and nitric oxide.
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Intra-uterine growth restriction has been reported to be
associated with increased risk of PPHN.16 It is believed that
utero-placental insufficiency may lead to postnatal
pulmonary hypertension by two mechanisms: oligohy-
dramnios and chronic fetal hypoxia. Hypoxia increases
endothelial synthesis of vasoconstrictors and smooth
muscle mitogens such as endothelin-1, platelet-derived
growth factor-b and vascular endothelial growth factor; itTable 1 Classification of persistent pulmonary hyperten-
sion of the newborn (PPHN).
- Abnormally constricted pulmonary vasculature caused
by parenchymal diseases:
- Meconium aspiration syndrome
- Respiratory distress syndrome30
- Pneumonia
- Hypoplastic pulmonary vasculature:
- Congenital diaphragmatic hernia
- Lung hypoplasia
- Normal parenchyma with remodeled pulmonary
vasculature:
- Idiopathic PPHN
- Congenital heart disease
- Hypoxiceischemic encephalopathy, chronic
- Othersalso inhibits eNOS. Increased thickness of right ventricular
wall, a hallmark of pulmonary hypertension, is also
commonly seen in animal models of intra-uterine growth
restriction.
Maternal SSRI exposure
SSRIs, which are commonly prescribed antidepressants,
have been reported to be associated with PPHN, especially
during the late trimester, in a caseecontrol study.17 Some
later studies also demonstrated the increased risk of PPHN
in SSRI-exposed neonates. A similar finding was seen in a rat
study and it is believed to be the result of smooth muscle
cell proliferation in pulmonary arteries.18
In utero NSAID exposure
In utero NSAID exposure is considered a risk factor for PPHN
because most NSAIDs inhibit prostaglandin synthesis and in
utero exposure is believed to close the ductus arteriosus
prenatally. Alano et al studied meconium and found an
association between the existence of NSAID metabolites
and the development of PPHN.19
Genetic risk factors
The only genetic risk factor reported is the association
between heterozygote T1405N genotype of carbamoyl-
Pulmonary hypertension of the newborn 181phosphate synthetase and PPHN, possibly because of a lack
of substrate for eNOS.13 Epidemiologic studies suggest
Black maternal race and male newborns have a higher
chance of developing PPHN.
Management
Current therapies for PPHN include mechanical ventilation,
muscle paralysis/relaxation, sedation, alkalosis and vaso-
relaxants.20 Inhaled nitric oxide (INO) is currently regarded
as the gold standard therapy, but as many as 30% of patients
are nonresponsive to INO treatment.1(Table 2)
General management
A quiet environment with minimal stimulation is recom-
mended for PPHN management. It is known that bright light
or loud noise can affect the oxygenation. Body tempera-
ture should be maintained at a thermoneutral range
(37.0  0.5 C). Appropriate hydration and hematocrit
(40e50%) should be maintained. Polycythemia
(hematocrit > 55%) can increase blood viscosity and
pulmonary vascular resistance. Hypoglycemia and hypo-
calcemia should be avoided. Hypoglycemia may lead to
reduced ATP formation and ATP is a known agonist for
eNOS. Calcium is one of the critical cofactors for eNOS
activity and hypocalcemia may impair eNOS function and
should be corrected. Preductal oxygenation should be used
to adjust the ventilator support and SpO2 above 95% may be
appropriate. Some centers prefer to monitor the difference
between pre- and postductal SpO2 as an indicator for the
severity of PPHN, although we do not regularly use this. For
severe PPHN shunting through the foramen ovale we can
observe fluid infusion through an intravenous catheter
below the diaphragm through the foramen ovale, so it isTable 2 Management of persistent pulmonary hyperten-
sion of the newborn (PPHN).
- General:
- Reduce stimulation: noise control, dim ambient
light, thermoneutral control
- Sedation and/or muscle relaxation
- Empirical antibiotics
- Avoid hypoglycemia
- Avoid hypocalcemia
- Nutritional support
- Alkalosis: questionable benefit
- Inotropic agent
- Mechanical ventilation:
- Conventional mechanical ventilation: pressure
limited or volume-controlled ventilator
- High-frequency (oscillator or jet) ventilator
- Vasorelaxant:
- Inhaled nitric oxide
- Prostaglandin: PGE1 or PGI2
- Others: sildenafil, MgSO4, milrinone
- Extracorporeal membrane oxygenator: VA- and
VV-typereasonable to provide pressor(s) via such a line in order to
reduce the effect on the pulmonary arteries. Empirical
antibiotics, such as ampicillin and gentamicin, are recom-
mended before infection (especially group B streptococcus)
can be ruled out as the cause of PPHN.
Severity of PPHN
Two parameters, alveolarearterial oxygen difference
(AaDO2) and oxygenation index (OI), are used most
frequently in PPHN management to judge the severity and
progress of the disease. AaDO2 is the difference between
alveolar oxygen content and arterial oxygen content. The
formula to calculate AaDO2 is:
AaDO2 Z ðATM  PH2OÞ  FiO2  PaO2  PaCO2=RQ
ATM is the atmospheric pressure, which is usually equal
to 760 torr (5.7 Pascal) at sea level but needs to be adjusted
in high altitude. PH2O is the pressure of water vapor in 1
ATM, which is usually considered to be 47 torr (0.35 Pascal).
FiO2 is the fraction of inspired air provided by the venti-
lator. The reason to correct for PaCO2 is because some
oxygen used to produce CO2 is from the nutrient inside the
body. RQ is the respiratory quotient and RQ Z 1 if the
energy source is purely sugar or RQ Z 0.8 when the nutri-
tional source is a combination of glucose, protein and lipid.
The clinical decision to use ECMO usually depends on
AaDO2. When AaDO2 is above 600 twice with maximal
support then ECMO can be considered. The oxygenation
index is more commonly used during medical management
of PPHN because it also considers ventilator support. The
oxygenation index is calculated as:
OIZ MAP  FiO2  100=PaO2
MAP is the mean airway pressure provided by the
ventilator. OI below 10 is usually considered to be mild
PPHN, OI between 10 and 20 is considered to be moderate
PPHN, whereas OI above 20 is considered to be severe
PPHN. If the OI remains above 20 under maximal medical
support, we usually recommend ECMO treatment if it is
available.
Mechanical ventilation
Mild PPHN can be managed by nasal cannula whereas
moderate and severe PPHN requires positive pressure
ventilator. High oxygen concentration and low PaCO2 are
commonly used for PPHN in the belief that both can help to
relax the pulmonary arteries. However, it is recommended
that PaCO2 levels should not be lower than 35 torr (0.263
Pascal) since CO2 also controls cerebral perfusion. Aggres-
sive hyperventilation with hypocapnia is known to be
a significant risk factor for hearing impairment in PPHN
survivors.21 Both a conventional mechanical ventilator and
a high-frequency (oscillator or jet) ventilator (HFOV or
HFJV) can be used. In severe PPHN most centers prefer
HFOV because this model usually will remove the patient’s
spontaneous breathing.
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Agitation usually aggravates PPHN with initial transient
increase of oxygenation followed by a precipitous drop in
oxygenation. To remove this flip-flop phenomenon in PPHN
management some centers will paralyze PPHN patients.
Sedation
Continuous sedation, either by benzodiazepine or a narcotic
agent, is a common practice in PPHNmanagement. Sedation
can decrease the frequency of desaturations.
Alkalosis
Induction of alkalosis by either infusion of sodium bicar-
bonate or hyperventilation has frequently been used as part
of the PPHN treatment. However, there is no solid evidence
to show that this practice is effective. A multicenter
observational study demonstrated an increased ECMO
requirement for patients receiving NaHCO3 infusion before
the INO era. It is hypothesized that NaHCO3 infusion
increases CO2 formation and leads to increases in ventilator
support.20
Inotropic agents and vasopressors
An increased right-to-left shunt is believed to be the main
reason for the severe hypoxemia in PPHN, so decreasing the
right-to-left shunt may be beneficial in PPHN. b-Adrenergic
agonists can decrease pulmonary vascular resistance more
than systemic vascular resistance and might have a more
favorable effect in PPHN especially in cases with poor
myocardial function such as in birth asphyxia associated
with PPHN.22 Dopamine increases both systemic and
pulmonary vascular resistance and reduces left-to-right
ductal shunting in preterm infants which suggests that it
may not be a good choice for premature infants with patent
ductus arteriosus and PPHN.23
Vasorelaxants
The most effective vasorelaxants for PPHN work specifically
on the pulmonary vasculature. However, unfortunately,
there is so far no specific vasorelaxant for the pulmonary
arteries. Several vasorelaxants have been used over the
past 4 decades, including epinephrine (b-adrenergic
receptor agonist), tolazoline (nonselective competitive a-
adrenergic receptor antagonist or histamine release),
magnesium sulfate etc. Prostanoids (PGE1 or PGI2) have
been suggested recently when the cause of severe hypox-
emia remains uncertain before ductal-dependent cyanotic
heart disease can be ruled out. Prostanoids help to relax
the vascular smooth muscle cells, and maintain the patency
of ductus arteriosus, though cAMP formation. However,
because of their nonspecificity, and potential side effect of
apnea, a secure airway is needed and the possibility of low
blood pressure should always be considered. Prostacyclin
(PGI2) and its analogues have been used more commonly
than PGE2 recently. Epoprostanol is an intravenouslyadministered analogue of PGI2, whereas iloprost is an
inhaled analogue. Presently the experience of PGI2
analogues for PPHN remains limited, but inhaled iloprost is
considered to be a more appropriate route to provide more
selective effect.
Nitric oxide (NO) is considered to be the most specific
pulmonary artery vasodilator because of its method of
administration. By increasing the intracellular cGMP in the
smooth muscle cells of the pulmonary arteries NO can
decrease the pulmonary vascular resistance. Inhaled nitric
oxide (INO) at a dose of 5 ppm significantly reduces the
combined outcome of death and need for ECMO by 35% in
infants with oxygen index of 25. However, long-term
follow-up studies (12e24 months) indicate that INO does
not alter either the incidence of chronic lung disease or
neurodevelopmental impairment.24,25 Early use of INO in
the disease course does not reduce the use of ECMO,
mortality, or improve other outcomes. INO above 20 ppm
does not provide more benefit and should be avoided.
Special arrangement is needed if INO is provided when the
patient is on an HFJV. NO can oxidize hemoglobin into
methemoglobin and levels of methemoglobin should be
monitored regularly because some patients may not
detoxify it as a result of enzyme deficiency. INO is not
universally effective and about 30% of patients with severe
PPHN do not respond to INO.
Original approved INO use is when OI is above 25, but
a recent trend is to start it when OI reaches 20. There is no
consensus regarding the OI threshold to initiate INO and
most centers establish their own criteria according to their
own experience and the availability of the ECMO facility.
When ECMO locates far away from the care center then
some centers will initiate INO when OI reaches 15 twice,
several (2e6) hours apart. The initial dose is usually 10 ppm
and it is increased or decreased, according to the clinical
response. Lower concentrations of INO (5e10 ppm) have
been studied, but the results remain unclear.
Extracorporeal membrane oxygenator (ECMO)
When all medical treatment fails then ECMO should be
considered when the PPHN’s cause is reversible. Chromo-
somal anomaly, lethal congenital malformation, uncor-
rectable heart defect, and major intracranial bleed
prohibit the use of ECMO. The course of ECMO is usually set
between 10 and 14 days according to individual institutional
guidelines. If the patient does not respond to ECMO during
this period then they will be decannulated and put back on
the original management plan. Two types of ECMO can be
used, including veno-venous (VV) and veno-arterial (VA).
VA-ECMO needs cannulation of one vein and one artery,
usually one external jugular vein and one internal carotid
artery. The problem with VA-ECMO is that an internal
carotid artery is sacrificed and there is an increased chance
of intracranial bleeding. VV-ECMO can be performed using
a double-lumen catheter without sacrificing any arteries.
However, a bigger catheter is required for VV-ECMO and
a good pumping heart is mandatory for the technique. The
patient’s size should be considered for ECMO use: they
need to be at least 2 kg in weight and usually more than
34 weeks’ gestation in order to be cannulated. During ECMO
treatment the patient has to be maintained on a low
ventilator setting to keep the alveoli open. Coagulation
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massive bleeding. The chance of having an intracranial
bleed is about 10e15% for ECMO, and this should be
explained to the family before the procedure. Well-trained
perfusionists are required and regular wet-runs should be
performed to maintain skill levels in ECMO centers. Since
the introduction of INO the number of ECMO centers has
declined dramatically, because of the cost of maintenance.
Others
L-Arginine is the substrate for eNOS and has been shown to
improve eNOS function in vitro, but it fails to show benefit
in vivo. However, L-citrulline, a precursor of L-arginine, can
enter endothelial cells effectively and has been shown to
ameliorate the severity of hypoxia-induced pulmonary
hypertension in an animal model.26 It is believed the
differential effect is because L-arginine cannot enter
endothelial cells to recouple the eNOS function. Endothelin
receptor antagonists have been investigated as potential
vasorelaxants, but their clinical usefulness remains
unknown. Bosentan is the only commercially available
endothelin receptor antagonist and a few case reports are
available in the literature. Magnesium inhibits calcium
entry into smooth muscle cells and, as a result, it is an
effective vasorelaxant.27 Tolazoline is an active vaso-
relaxant, especially when administered by way of inhala-
tion. There are also case series, or reports, about the effect
of magnesium and tolazoline use in PPHN, but large-scale
randomized controlled trials are lacking for both. Adeno-
sine is a vasorelaxant with an extremely short half-life and
is an eNOS agonist that increases the formation of NO.
Because of its short half-life there may be fewer systemic
side effects with adenosine. However, presently there is
limited experience with adenosine in PPHN.28
Recently there is an interest in phosphodiesterase (PDE)
inhibitors, especially the type 5 inhibitors.7 There are at
least more than 11 types of PDE that hydrolyze cAMP, cGMP
or both. Type 5 is the main PDE in the pulmonary vascula-
ture, genital organ and auditory system. Inhibiting PDE-5
can maintain intracellular cGMP levels and prolong the
effect of NO in pulmonary arteries. There have been
several case series and one randomized controlled trial
using sildenafil (0.5e2.0 mg/kg every 6 hours), a PDE-5
inhibitor, in managing PPHN with success.29 Milrinone is
a type 3 PDE inhibitor that decreases hydrolysis of cAMP.
Dosage between 0.2 and 1 mg/kg/min with or without
loading (20e50 mg/kg) of milrinone has been reported when
patients fail to respond INO. PGI2 relaxes the pulmonary
artery via increasing intravascular cAMP levels, so milrinone
may be helpful in treating PPHN. There are a few case
series that demonstrated the efficacy of milrinone use in
PPHN. However, since milrinone also decreases the
systemic vasculature resistance, it may aggravate the right-
to-left shunt so its use is recommended only when poor
systemic perfusion is considered to affect the PPHN treat-
ment. ET-1 is another important pulmonary vasoconstrictor
that contributes to PPHN and use of an ET-1 dual antagonist
(Bosentan) has been reported in a few neonates with
severe PPHN. A recent single-center, randomized, blinded,
controlled trial of Bosentan 1 mg/kg twice daily via
a feeding tube was reported against placebo withoutinhaled NO treatment and showed a dramatic decrease in
mortality and better neurological outcome.30
Surfactants have been studied in animal models of PPHN
induced by meconium aspiration. They have also been
combined with an NO donor, or sildenafil, in other types of
PPHN with some success. A clinical trial of surfactants in
PPHN has been reported in human neonates with MAS under
the belief that meconium can inhibit surfactant protein
function or used as an airway toilet to wash out the
meconium in the airway.31 A recent Australian multicenter
study reconfirmed the efficacy of surfactant in MAS espe-
cially in places where ECMO is not available.16 Superoxide
dismutase (SOD), or its mimetics, has been studied by both
Steinhorn and Black groups. Both groups show some
promise of using SOD in animal models of PPHN.32 The
mechanism may be secondary to the removal of O2
 that
leads to an increased bioavailability of NO and increased
apoptosis of pulmonary artery smooth muscle cells.3335
Tetrahydrobiopterin (BH4) is not only a vital cofactor for
eNOS function but also an important intracellular antioxi-
dant. Depletion of BH4, or oxidation of BH4 into dihy-
drobiopterin (BH2), can uncouple eNOS function and shift
eNOS from NO formation into O2
 formation. NO not only
relaxes arteries but also mediates blood vessel formation
(angiogenesis). Methods to increase endothelial cell BH4
content might improve eNOS function and help angio-
genesis. We recently demonstrated that sepiapterin,
a precursor for BH4, can recouple eNOS and correct the
impaired angiogenesis in PPHN pulmonary artery endothe-
lial cells.36 Some other antioxidants, such as N-acetylcye-
teine, apocynin and ascorbate, can either decrease
intracellular ROS formation or increase BH4 levels which
may help to improve NO bioavailability but their efficacy
has not been demonstrated in human infants.
Outcome
Survivors have high morbidity in the form of neuro-
developmental and audiological impairment, cognitive
delays, hearing loss, and a high rate of rehospitalization. A
low PaCO2 level, usually because of hyperventilation, is
considered to be a contributing factor for hearing loss
especially when combined with the prolonged use of ami-
noglycoside treatment.
Conclusion
Even with advances in PPHN treatment the mortality rate of
this lung disease remains high. Animal models of PPHN
provide insight into potential treatment modalities and
pathophysiology, but cannot completely reflect the
disease. Decreased ambient stimulation, continuous seda-
tion, appropriate mechanical ventilation, and inhaled NO
treatment are the cornerstones of PPHN management.
ECMO should be provided when maximal medical treatment
fails. Head ultrasound and echocardiography should be
performed before the discussion about ECMO use. VV-ECMO
is the preferred mode of ECMO when myocardial function is
adequate. Potential therapeutic modalities such as PDE
inhibitors, intravenous citrullin infusion, or BH4 treatment
require more studies before clinical application.
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